A Phase II, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Multi-Center Study to Explore the Efficacy, Safety and Tolerability of VK5211 in Subjects With Acute Hip Fracture

Trial Profile

A Phase II, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Multi-Center Study to Explore the Efficacy, Safety and Tolerability of VK5211 in Subjects With Acute Hip Fracture

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs VK 5211 (Primary)
  • Indications Hip fracture
  • Focus Therapeutic Use
  • Sponsors Viking Therapeutics
  • Most Recent Events

    • 28 Nov 2017 According to a Viking Therapeutics media release, additional results are expected to present at an upcoming scientific conference.
    • 28 Nov 2017 According to a Viking Therapeutics media release, primary endpoint has been met. (Increases in total lean body mass, less head)
    • 28 Nov 2017 Topline results presented in a Viking Therapeutics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top